ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2013
HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Homeobox B13 G84E Mutation and Prostate Cancer Risk.European urology · 2019Pooled it
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.Oncotarget · 2016Pooled it
- Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.Oncotarget · 2015Pooled it
- G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- Association Between Dietary Folate and Prostate Cancer Aggressiveness Among African Americans and European Americans.Nutrients · 2026Article
- Temporal trends and regional disparities in prostate cancer mortality in the United States, 1999-2023: an analysis of the CDC WONDER database.BMC public health · 2025Article
- Integrating molecular diagnostics for early prostate cancer detection.Oncoscience · 2025Article
- Germline Variants in DNA Damage Repair Genes andJCO precision oncology · 2022Article
- Single nucleotide polymorphisms in microRNA binding sites on theBiochemistry and biophysics reports · 2021Article
- Prostate cancer risk variants of the HOXB genetic locus.Scientific reports · 2021Article
- Review
- Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent.Frontiers in oncology · 2021Review
- Diagnosing hereditary cancer predisposition in men with prostate cancer.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Article
- Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.International journal of molecular sciences · 2018Review
- Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours.Scientific reports · 2017Article
- Familial prostate cancer.Seminars in oncology · 2016Article
- Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.Scientific reports · 2016Article
- Oncogenic mechanisms ofOncoscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundRecent work detected for the first time a high-risk prostate cancer mutation, in homeobox B13 (HOXB13) among European-Americans.
methodsWe further evaluated this G84E missense mutation (rs138213197) in two genetic association studies of prostate cancer: a family-based study of brothers and a case-control study of more aggressive disease (N = 2,665 total). We then calculated overall impact of this mutation by pooling all published studies of European-Americans.
resultsIn our studies, the mutation was found exclusively among men with prostate cancer (carrier frequency = 1.48%) or unaffected brothers of cases carrying the mutation (frequency = 0.34%), and carrying the mutation gave an OR for disease = 4.79 (P = 0.01). The G84E mutation was more common among men with an earlier age of onset (≤55 years) or a family history of prostate cancer. We also observed for the first time an African-American case carrying the G84E mutation, although at HOXB13 both of his chromosomes were of European-American ancestry. The pooled analysis also indicated that carrying the G84E mutation results in an almost five-fold increase in risk of prostate cancer (P = 3.5 × 10(-17)), and this risk is even higher among cases with an early age of prostate cancer onset (≤55 years) or a family history of disease: a test of heterogeneity across these strata gives P < 1 × 10(-5).
conclusionsThe HOXB13 mutation substantially increases risk of early onset, familial prostate cancer in European-American men. IMPACT: Testing for the G84E mutation in men with a positive family history may help distinguish those who merit more regular screening for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.